Browsing Tag
NASDAQ: HOTH
2 posts
Hoth Therapeutics (NASDAQ: HOTH) stakes claim on emerging oncodermatology space with dual patent filings for HT-001
Hoth Therapeutics files dual patents for HT-001 in oncology dermatology. Find out what this means for its IP strategy and cancer care positioning.
January 5, 2026
Hoth Therapeutics advances HT-KIT: Preclinical success sets stage for human trials and stock market interest
Hoth Therapeutics reports tumor suppression with no toxicity for HT-KIT. Learn how this biotech play could reshape cancer care and investor sentiment.
May 12, 2025